Immune checkpoint therapy for pancreatic cancer

Table 3 Clinical trials on programmed cell death ligand 1

Target molecule	Drug name	Study phase	Study design	Status	Condition	Intervention	Cohort	Estimated enrollment	Dose	End point	Study Arm	Adverse event	Response	Survival	Ref.
PD-L1	Durvalumab (MEDI4736)	2	Non-randomized	Not recruiting	PC, GeC, OC, NSCLC, BC, RCC, CrC	Palliative	Metastatic	136	750 mg > 30 kg,	Safety Efficacy (ORR, PFS, OS)	Durvalumab	NA	NA	NA	NCT02669914
									10 mg/kg < 30 kg
		2	NA	Recruiting	PC, BlC, BC	Palliative	Metastatic	77	NA	Safety	Tremelimumab (Arm A)	NA	NA	NA	NCT02527434
										Efficacy (ORR, DoR, DCR, PFS, OS, BoR)	Durvalumab (Arm B)
											Tremelimumab, Durvalumab (Arm C)
		1	Non-randomized	Recruiting	PC, HNSCC, MM, CrC, BC, CEC	Palliative	Locally advanced	40	NA	Safety (AE)	Durvalumab, Selumetinib	NA	NA	NA	NCT02586987
							Metastatic			Efficacy (ORR, BoR, DoR)
										Tolerability
										PK
		2	Randomized	Recruiting	PC	Palliative	Metastatic	130	NA	Safety	Durvalumab (Arm A)	NA	NA	NA	NCT02558894
										Efficacy (ORR, DoR, DCR, PFS)	Durvalimab, Tremelimumab (Arm B)
										PK
										Antidrug Antibody Presence
		1|2	Non-randomized	Recruiting	PC	Palliative	Metastatic	26	NA	Safety (DLT)	Durvalumab , nab-Paclitaxel, Gemcitabine (Arm A)	NA	NA	NA	NCT02583477
										Efficacy (ORR, DoR, DCR, PFS)	Durvalumab, AZD5069 (Arm B)
										PK
		1	Randomized	Recruiting	PC, NSCLC, HNSCC	Palliative	Locally advanced	108	NA	Safety (AE, DLT)	Durvalumab, Mogamulizumab (Arm A)	NA	NA	NA	NCT02301130
							Metastatic				Tremelimumab, Mogamulizumab (Arm B)
		1	Non-randomized	Recruiting	PC, NSCLC, BC, MM	Palliative	Metastatic	30	1 mg/kg	Safety (AE)	Durvalumab, Tremelimumab, Radiotherapy	NA	NA	NA	NCT02639026
										Efficacy

NA: Not available.